Trial Outcomes & Findings for A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching (NCT NCT06150573)

NCT ID: NCT06150573

Last Updated: 2025-07-24

Results Overview

Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

160 participants

Primary outcome timeframe

At Week 24 after tooth bleaching

Results posted on

2025-07-24

Participant Flow

This study was conducted at a single center in the United States.

A total of 178 participants were screened into the study, 160 participants were enrolled and randomized to treatment (79 participants in the test dentifrice group and 81 participants in the reference dentifrice group). A total of 154 randomized participants completed the study.

Participant milestones

Participant milestones
Measure
Test Dentifrice
Participants dosed the toothbrush provided with a strip of test dentifrice (5 percent \[%\] Potassium nitrate \[KNO3\], 1% alumina, 5% Sodium tripolyphosphate \[STP\] and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Overall Study
STARTED
79
81
Overall Study
COMPLETED
75
79
Overall Study
NOT COMPLETED
4
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Test Dentifrice
Participants dosed the toothbrush provided with a strip of test dentifrice (5 percent \[%\] Potassium nitrate \[KNO3\], 1% alumina, 5% Sodium tripolyphosphate \[STP\] and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Overall Study
Did not meet study criteria
1
0
Overall Study
Adverse Event
1
0
Overall Study
Lost to Follow-up
0
1
Overall Study
Protocol Violation
0
1
Overall Study
Withdrawal by Subject
2
0

Baseline Characteristics

A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Test Dentifrice
n=79 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Total
n=160 Participants
Total of all reporting groups
Age, Continuous
42.0 years
STANDARD_DEVIATION 11.91 • n=5 Participants
37.6 years
STANDARD_DEVIATION 13.04 • n=7 Participants
39.8 years
STANDARD_DEVIATION 12.65 • n=5 Participants
Sex: Female, Male
Female
47 Participants
n=5 Participants
45 Participants
n=7 Participants
92 Participants
n=5 Participants
Sex: Female, Male
Male
32 Participants
n=5 Participants
36 Participants
n=7 Participants
68 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
22 Participants
n=5 Participants
21 Participants
n=7 Participants
43 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
57 Participants
n=5 Participants
60 Participants
n=7 Participants
117 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race/Ethnicity, Customized
African American/African Heritage
13 Participants
n=5 Participants
13 Participants
n=7 Participants
26 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian - East Asian Heritage
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian - Japanese Heritage
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian - South East Asian Heritage
7 Participants
n=5 Participants
5 Participants
n=7 Participants
12 Participants
n=5 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
4 Participants
n=5 Participants
6 Participants
n=7 Participants
10 Participants
n=5 Participants
Race/Ethnicity, Customized
White - Arabic/North African Heritage
4 Participants
n=5 Participants
3 Participants
n=7 Participants
7 Participants
n=5 Participants
Race/Ethnicity, Customized
White - White/Caucasian/European Heritage
42 Participants
n=5 Participants
41 Participants
n=7 Participants
83 Participants
n=5 Participants
Race/Ethnicity, Customized
Multiple
7 Participants
n=5 Participants
12 Participants
n=7 Participants
19 Participants
n=5 Participants

PRIMARY outcome

Timeframe: At Week 24 after tooth bleaching

Population: The modified Intent-To-Treat (mITT) population included all randomized participants who completed at least one use of study product and had at least one assessment of tooth color after the bleaching period. Only those participants with data available at the specified time point were analyzed.

Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=75 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=79 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching
12.00 score on a scale
Standard Error 0.355
12.06 score on a scale
Standard Error 0.348

SECONDARY outcome

Timeframe: At Week 12 after tooth bleaching

Population: The mITT population. Only those participants with data available at the specified time point were analyzed.

Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=72 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=77 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching
12.08 score on a scale
Standard Error 0.353
11.71 score on a scale
Standard Error 0.346

SECONDARY outcome

Timeframe: At Week 12 and Week 24 after tooth bleaching

Population: The mITT population. Only those participants with data available at the specified time points were analyzed.

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
0.69 score on a scale
Standard Error 0.044
0.87 score on a scale
Standard Error 0.043
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
0.72 score on a scale
Standard Error 0.053
1.03 score on a scale
Standard Error 0.052

SECONDARY outcome

Timeframe: At Week 12 and Week 24 after tooth bleaching

Population: The mITT population. Only those participants with data available at the specified time points were analyzed.

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Gingival MLSI, Week 12
0.02 score on a scale
Standard Error 0.012
0.03 score on a scale
Standard Error 0.011
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Gingival MLSI, Week 24
0.01 score on a scale
Standard Error 0.014
0.05 score on a scale
Standard Error 0.014
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Body MLSI, Week 12
0.00 score on a scale
Standard Error 0.007
0.01 score on a scale
Standard Error 0.007
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Interproximal MLSI, Week 12
1.37 score on a scale
Standard Error 0.088
1.71 score on a scale
Standard Error 0.086
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Interproximal MLSI, Week 24
1.44 score on a scale
Standard Error 0.105
2.04 score on a scale
Standard Error 0.103
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Mean Body MLSI, Week 24
0.00 score on a scale
Standard Error 0.005
0.01 score on a scale
Standard Error 0.004

SECONDARY outcome

Timeframe: At Week 12 and Week 24 after tooth bleaching

Population: The mITT population. Only those participants with data available at the specified time points were analyzed.

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
0.55 score on a scale
Standard Error 0.025
0.69 score on a scale
Standard Error 0.024
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
0.57 score on a scale
Standard Error 0.027
0.74 score on a scale
Standard Error 0.027

SECONDARY outcome

Timeframe: At Week 12 and Week 24 after tooth bleaching

Population: The mITT population. Only those participants with data available at the specified time points were analyzed.

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.

Outcome measures

Outcome measures
Measure
Test Dentifrice
n=78 Participants
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 Participants
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
Week 12
0.46 score on a scale
Standard Error 0.023
0.52 score on a scale
Standard Error 0.023
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
Week 24
0.48 score on a scale
Standard Error 0.027
0.60 score on a scale
Standard Error 0.026

Adverse Events

Test Dentifrice

Serious events: 1 serious events
Other events: 39 other events
Deaths: 0 deaths

Reference Dentifrice

Serious events: 1 serious events
Other events: 42 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Test Dentifrice
n=79 participants at risk
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 participants at risk
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.

Other adverse events

Other adverse events
Measure
Test Dentifrice
n=79 participants at risk
Participants dosed the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Reference Dentifrice
n=81 participants at risk
Participants dosed the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and brushed for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice was used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants performed the first application of peroxide tooth bleaching as per the instructions provided and continued the application daily for up to 7 days.
Gastrointestinal disorders
GINGIVAL PAIN
19.0%
15/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
25.9%
21/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
HYPERAESTHESIA TEETH
11.4%
9/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
18.5%
15/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
ORAL MUCOSAL EXFOLIATION
8.9%
7/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
2.5%
2/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
ANGULAR CHEILITIS
5.1%
4/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
CHRONIC CHEEK BITING
3.8%
3/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
GINGIVAL DISCOMFORT
3.8%
3/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
LIP DRY
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
NAUSEA
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
NONINFECTIVE GINGIVITIS
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Gastrointestinal disorders
ORAL DISCOMFORT
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Injury, poisoning and procedural complications
TRAUMATIC ULCER
19.0%
15/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
23.5%
19/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Injury, poisoning and procedural complications
GINGIVAL INJURY
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Infections and infestations
SINUSITIS
1.3%
1/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
0.00%
0/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Vascular disorders
DEEP VEIN THROMBOSIS
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
Vascular disorders
HYPERTENSION
0.00%
0/79 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.
1.2%
1/81 • From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A serious adverse event (SAE) is a particular category of AE where the adverse outcome is serious.

Additional Information

Haleon Response Center

HALEON

Phone: +441932959500

Results disclosure agreements

  • Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER